KROS

#3568
Keros Therapeutics, Inc. - common stock
11.0 3 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
11.03
11.03
Intervallo Annuale
9.69
22.55
Variazione giornaliera
-1.78%
Variazione Mensile
+8.56%
Variazione di 6 mesi
-21.21%
Variazione Annuale
-26.95%
Chiusura Precedente
11.2 3
Open
11.0 3
Minimo
11.0 3
Massimo
11.0 3
Volume
46
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Keros Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Keros Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q

Keros Therapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

Keros Therapeutics, Inc. (KROS) filed this Form 8-K to report the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

Stockholders voted on three proposals at the Annual Meeting. The results were as follows:

  • Proposal 1 (Election of Directors): Stockholders elected Jean-Jacques Bienaimé and Charles Newton to serve until the 2029 Annual Meeting.
    • Jean-Jacques Bienaimé: 10,093,559.27 votes for; 5,156,153 votes withheld.
    • Charles Newton: 14,716,598 votes for; 533,114 votes withheld.
  • Proposal 2 (Ratification of Auditors): Stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
    • Votes For: 16,708,279.27
    • Votes Against: 783,953
    • Votes Abstain: 994
  • Proposal 3 (Advisory Vote on Executive Compensation): Stockholders approved the compensation of named executive officers on a non-binding advisory basis.
    • Votes For: 14,273,625.27
    • Votes Against: 974,049
    • Votes Abstain: 2,038

Guidance, Outlook, and Risks

This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the outcomes of the shareholder vote.

Key Facts for Investor Verification

  • Verify the definitive proxy statement filed on April 22, 2026, for detailed biographies of the elected directors and executive compensation specifics.
  • Note that Jean-Jacques Bienaimé received a significant number of withheld votes (approximately 34% of votes cast for that nominee) compared to Charles Newton.
  • Confirm the company's financial status and cash runway through its most recent 10-Q or 10-K filing, as this 8-K contains no financial data.

Notizie